Idenix Pharmaceuticals, Inc. (NASDAQ:IDIX)

CAPS Rating: 2 out of 5

A biopharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of human viral and other infectious diseases with operations in the United States and Europe.

Recs

1
Player Avatar zzlangerhans (99.78) Submitted: 6/4/2013 10:25:06 PM : Underperform Start Price: $4.88 IDIX Score: +21.91

I find it difficult to value hepatitis C stocks but Idenix has risen sharply over the last three weeks without a clear precipitant that I can identify. The company announced plans for a phase II trial of all-oral combination of IDX719 and Janssen's simeprevir in their last earnings call, but this was fairly predictable after the announcement of the Janssen collaboration in January. Hepatitis C may still be an exciting and lucrative field but there's loads of competition and Idenix seems to be years behind in the development of all oral regimens.

Featured Broker Partners


Advertisement